

BIO-TECHNE Corp  
 Form 3  
 December 03, 2014

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|                                                   |         |                                      |                                                                            |                                                                        |
|---------------------------------------------------|---------|--------------------------------------|----------------------------------------------------------------------------|------------------------------------------------------------------------|
| 1. Name and Address of Reporting Person *         |         | 2. Date of Event Requiring Statement | 3. Issuer Name and Ticker or Trading Symbol                                |                                                                        |
| Gavin Robert M.                                   |         | (Month/Day/Year)                     | BIO-TECHNE Corp [TECH]                                                     |                                                                        |
| (Last)                                            | (First) | (Middle)                             | 11/25/2014                                                                 |                                                                        |
| C/O BIO-TECHNE CORPORATION, 614 MCKINLEY PLACE NE |         |                                      | 4. Relationship of Reporting Person(s) to Issuer                           | 5. If Amendment, Date Original Filed(Month/Day/Year)                   |
| (Street)                                          |         |                                      | (Check all applicable)                                                     |                                                                        |
| MINNEAPOLIS, MN 55413                             |         |                                      | <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner       | 6. Individual or Joint/Group Filing(Check Applicable Line)             |
| (City)                                            | (State) | (Zip)                                | <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other | <input checked="" type="checkbox"/> Form filed by One Reporting Person |
|                                                   |         |                                      | (give title below) (specify below)                                         | <input type="checkbox"/> Form filed by More than One Reporting Person  |
|                                                   |         |                                      | Sen. VP Protein Platforms                                                  |                                                                        |

**Table I - Non-Derivative Securities Beneficially Owned**

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|-------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|
| Common Stock                    | 5,000 <sup>(1)</sup>                                  | D                                                        |                                                       |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative | 5. Ownership Form of Derivative Security: | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--------------------------------------------|----------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------|-------------------------------------------|-------------------------------------------------------|
|--------------------------------------------|----------------------------------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------|-------------------------------------------|-------------------------------------------------------|

Edgar Filing: BIO-TECHNE Corp - Form 3

|              | Date Exercisable          | Expiration Date | Title        | Amount or Number of Shares | Security | Direct (D) or Indirect (I) (Instr. 5) |   |
|--------------|---------------------------|-----------------|--------------|----------------------------|----------|---------------------------------------|---|
| Stock Option | 07/31/2015 <sup>(2)</sup> | 07/31/2021      | Common Stock | 10,000                     | \$ 93.32 | D                                     | Â |
| Stock Option | 01/01/2017 <sup>(3)</sup> | 07/31/2021      | Common Stock | 50,000                     | \$ 93.32 | D                                     | Â |

## Reporting Owners

| Reporting Owner Name / Address                                                                  | Relationships |           |                             |       |
|-------------------------------------------------------------------------------------------------|---------------|-----------|-----------------------------|-------|
|                                                                                                 | Director      | 10% Owner | Officer                     | Other |
| Gavin Robert M.<br>C/O BIO-TECHNE CORPORATION<br>614 MCKINLEY PLACE NE<br>MINNEAPOLIS, MN 55413 | Â             | Â         | Â Sen. VP Protein Platforms | Â     |

## Signatures

/s/ Robert M. Gavin 12/03/2014

\*\*Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 5,000 restricted stock units that represent a contingent right to receive one share of Bio-Techne Corporation common stock. The restricted stock units vest if certain performance goals are achieved for calendar 2016.
- (2) Vests 2,500 on each of 7/31/2015, 7/31/2016, 7/31/2017 and 7/31/2018.
- (3) Includes 50,000 common stock options. The options vest if certain performance goals are achieved for calendar 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.